Show simple item record

dc.contributor.authorBarge-Caballero, Gonzalo
dc.contributor.authorBarge-Caballero, Eduardo
dc.contributor.authorLópez-Pérez, Manuel
dc.contributor.authorBilbao-Quesada, Raquel
dc.contributor.authorGonzález-Babarro, Eva
dc.contributor.authorGómez-Otero, Inés
dc.contributor.authorLópez-López, Andrea
dc.contributor.authorGutiérrez-Feijoo, Mario
dc.contributor.authorVarela-Román, Alfonso
dc.contributor.authorGonzález-Juanatey, Carlos
dc.contributor.authorDíaz-Castro, Óscar
dc.contributor.authorCrespo-Leiro, María Generosa
dc.date.accessioned2022-12-15T07:40:23Z
dc.date.issued2022-02
dc.identifier.citationBarge-Caballero G, Barge-Caballero E, López-Pérez M, Bilbao-Quesada R, González-Babarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, González-Juanatey C, Díaz-Castro Ó, Crespo-Leiro MG. Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy. Mayo Clin Proc. 2022 Feb;97(2):261-273.es_ES
dc.identifier.issn0025-6196
dc.identifier.urihttp://hdl.handle.net/2183/32195
dc.description.abstract[Abstract] Objective: To investigate a potential association between beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Methods: In this real-world prospective registry of 128 consecutive patients with ATTR-CM recruited in 7 institutions in Galicia (Spain), survival of 65 patients who received beta blockers on registry enrollment was compared with that of 63 untreated controls by means of both unweighted Cox regression and Cox regression with inverse probability of treatment weighting. Tolerance to and adverse effects of beta blockers were recorded. Median study follow-up was 520 days. Results: Patients with ATTR-CM who received beta blockers showed statistically significant lower all-cause mortality than untreated controls as evaluated by either unweighted Cox regression (hazard ratio, 0.31; 95% CI, 0.12 to 0.79) or Cox regression with inverse probability of treatment weighting (hazard ratio, 0.18; 95% CI, 0.08 to 0.41; P<.001). Several sensitivity analyses confirmed the internal validity of these results. The overall frequency of beta-blocker suspension due to adverse effects was 25% (95% CI, 15.5% to 34.5%). Conclusion: In this real-world, prospective, multi-institutional registry, patients with ATTR-CM who received beta blockers had lower all-cause mortality than untreated controls.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.urihttps://doi.org/10.1016/j.mayocp.2021.08.006es_ES
dc.subjectAdrenergic beta-antagonistses_ES
dc.subjectAmyloid neuropathies, Familiales_ES
dc.subjectQuality of lifees_ES
dc.titleBeta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathyes_ES
dc.typeinfo:eu-repo/semantics/contributionToPeriodicales_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2023-02-01es_ES
dc.date.embargoLift2023-02-01
UDC.journalTitleMayo Clinic Procedingses_ES
UDC.volume97es_ES
UDC.issue2es_ES
UDC.startPage261es_ES
UDC.endPage273es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record